Literature DB >> 21969587

Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).

Guorong Li1, Xiaoli Du, William C Vass, Alex G Papageorge, Douglas R Lowy, Xiaolan Qian.   

Abstract

The deleted in liver cancer 1 (DLC1) tumor suppressor gene, which is frequently inactivated in cancer, encodes a Rho-GAP (GTPase activating protein) focal adhesion protein whose negative regulation of Rho-GTPases is necessary but not sufficient for its full tumor suppressor activity. Here, we report that DLC1 forms a complex with two prooncogenic focal adhesion proteins, talin and the focal adhesion kinase (FAK). We identified an 8-aa sequence (residues 469LDDILYHV476) in DLC1 and designated it an LD-like motif, because it shares homology with the LD motifs of paxillin. This motif was necessary for DLC1 binding to talin and FAK, because a DLC1 mutant, from which six of the residues have been deleted, and another mutant carrying amino acid substitutions in three of the residues are deficient for binding both proteins and localization of DLC1 to focal adhesions. FAK binding was independent of talin and vice versa. In bioassays, both DLC1 mutants were less active than wild-type (WT) DLC1, although the ability of the mutants to negatively regulate overall Rho-GTP was not impaired. We conclude that the LD-like motif, which binds talin and FAK, is required for the full tumor suppressor activity of DLC1 and contributes to the association of DLC1 with focal adhesions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21969587      PMCID: PMC3193248          DOI: 10.1073/pnas.1112122108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

Review 1.  Chapter 1. Focal adhesions: new angles on an old structure.

Authors:  Adi D Dubash; Marisa M Menold; Thomas Samson; Etienne Boulter; Rafael García-Mata; Renee Doughman; Keith Burridge
Journal:  Int Rev Cell Mol Biol       Date:  2009       Impact factor: 6.813

Review 2.  Paxillin LD motifs may define a new family of protein recognition domains.

Authors:  M C Brown; M S Curtis; C E Turner
Journal:  Nat Struct Biol       Date:  1998-08

3.  Ras-specific exchange factor GRF: oligomerization through its Dbl homology domain and calcium-dependent activation of Raf.

Authors:  P H Anborgh; X Qian; A G Papageorge; W C Vass; J E DeClue; D R Lowy
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

Review 4.  The genetics and genomics of cancer.

Authors:  Allan Balmain; Joe Gray; Bruce Ponder
Journal:  Nat Genet       Date:  2003-03       Impact factor: 38.330

5.  beta1 integrin cytoplasmic domain residues selectively modulate fibronectin matrix assembly and cell spreading through talin and Akt-1.

Authors:  J Angelo Green; Allison L Berrier; Roumen Pankov; Kenneth M Yamada
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

6.  Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.

Authors:  Xiaolan Qian; Guorong Li; Holly K Asmussen; Laura Asnaghi; William C Vass; Richard Braverman; Kenneth M Yamada; Nicholas C Popescu; Alex G Papageorge; Douglas R Lowy
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-15       Impact factor: 11.205

Review 7.  Paxillin comes of age.

Authors:  Nicholas O Deakin; Christopher E Turner
Journal:  J Cell Sci       Date:  2008-08-01       Impact factor: 5.285

8.  p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities.

Authors:  X-Y Yang; M Guan; D Vigil; C J Der; D R Lowy; N C Popescu
Journal:  Oncogene       Date:  2009-01-19       Impact factor: 9.867

9.  Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.

Authors:  Lo-Kong Chan; Frankie Chi Fat Ko; Irene Oi-Lin Ng; Judy Wai Ping Yam
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

Review 10.  DLC-1:a Rho GTPase-activating protein and tumour suppressor.

Authors:  Marian E Durkin; Bao-Zhu Yuan; Xiaoling Zhou; Drazen B Zimonjic; Douglas R Lowy; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more
  51 in total

1.  Solution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode.

Authors:  Lihong Chen; Changdong Liu; Frankie Chi Fat Ko; Naining Xu; Irene Oi-Lin Ng; Judy Wai Ping Yam; Guang Zhu
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

2.  The Deleted in Liver Cancer 1 (Dlc1) tumor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity.

Authors:  Pratima Basak; Rachelle Dillon; Heather Leslie; Afshin Raouf; Michael R A Mowat
Journal:  BMC Cancer       Date:  2015-09-09       Impact factor: 4.430

3.  Upregulation of DLC-1 inhibits pancreatic cancer progression: Studies with clinical samples and a pancreatic cancer model.

Authors:  Bo Chen; Mingzheng Xu; Ming Xu
Journal:  Oncol Lett       Date:  2019-09-16       Impact factor: 2.967

Review 4.  From mechanical force to RhoA activation.

Authors:  Elizabeth C Lessey; Christophe Guilluy; Keith Burridge
Journal:  Biochemistry       Date:  2012-09-10       Impact factor: 3.162

5.  Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression.

Authors:  David Sánchez-Martín; Atsushi Otsuka; Kenji Kabashima; Taekyu Ha; Dunrui Wang; Xiaolan Qian; Douglas R Lowy; Giovanna Tosato
Journal:  J Natl Cancer Inst       Date:  2018-04-01       Impact factor: 13.506

6.  Functional cross-talk between ras and rho pathways: a Ras-specific GTPase-activating protein (p120RasGAP) competitively inhibits the RhoGAP activity of deleted in liver cancer (DLC) tumor suppressor by masking the catalytic arginine finger.

Authors:  Mamta Jaiswal; Radovan Dvorsky; Ehsan Amin; Sarah L Risse; Eyad K Fansa; Si-Cai Zhang; Mohamed S Taha; Aziz R Gauhar; Saeideh Nakhaei-Rad; Claus Kordes; Katja T Koessmeier; Ion C Cirstea; Monilola A Olayioye; Dieter Häussinger; Mohammad R Ahmadian
Journal:  J Biol Chem       Date:  2014-01-17       Impact factor: 5.157

7.  Fluctuation of ROS regulates proliferation and mediates inhibition of migration by reducing the interaction between DLC1 and CAV-1 in breast cancer cells.

Authors:  Bingwu Yang; Wenzhen Zhu; Zhaodi Zheng; Rongfei Chai; Shuhua Ji; Guanghui Ren; Tingting Liu; Zhaojun Liu; Taiyu Song; Fenglin Li; Shan Liu; Guorong Li
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-01-27       Impact factor: 2.416

8.  Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.

Authors:  Archna Ravi; Shelly Kaushik; Aarthi Ravichandran; Catherine Qiurong Pan; Boon Chuan Low
Journal:  J Biol Chem       Date:  2014-12-18       Impact factor: 5.157

Review 9.  Leukocyte arrest: Biomechanics and molecular mechanisms of β2 integrin activation.

Authors:  Zhichao Fan; Klaus Ley
Journal:  Biorheology       Date:  2015       Impact factor: 1.875

Review 10.  Chapter 22: Structural and signaling functions of integrins.

Authors:  Yasmin A Kadry; David A Calderwood
Journal:  Biochim Biophys Acta Biomembr       Date:  2020-01-25       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.